| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.076 | 0.09 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.075 | 0.1 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.1 | 0.1 |
| mRNA | hyperforin | CTRPv2 | pan-cancer | AAC | 0.079 | 0.1 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.074 | 0.1 |
| mRNA | myriocin | CTRPv2 | pan-cancer | AAC | -0.13 | 0.1 |
| mRNA | tamatinib | CTRPv2 | pan-cancer | AAC | -0.072 | 0.1 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.062 | 0.1 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.066 | 0.1 |
| mRNA | myricetin | CTRPv2 | pan-cancer | AAC | 0.072 | 0.1 |